Last reviewed · How we verify

NCT07085793: ePVS

Estimated Plasma Volume in Patients With Acute Heart Failure

Completed Last updated 6 August 2025
What this trial tests

trial in Acute Heart Failure in 2,500 participants. Completed in 30 December 2023.

Timeline
1 January 2019
Primary endpoint
30 December 2023
30 December 2023

Quick facts

Lead sponsorUniversity of Monastir
StatusCompleted
Study typeOBSERVATIONAL
Enrollment2,500
Start date1 January 2019
Primary completion30 December 2023
Estimated completion30 December 2023
Sites1 location across Tunisia

Conditions studied

Sponsor

University of Monastir

Who can join

Adults 18 to 90, any sex, with Acute Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Congestion plays an essential role in acute heart failure (AHF) outcomes. Estimated plasma volume status (ePVS), derived from simple hematological parameters, may offer prognostic value. The objectif is to assess the prognostic value of admission ePVS, calculated using Duarte and Hakim formulas, for short- and long-term mortality and/or readmission in patients hospitalized for AHF.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Heart Failure

Currently open trials in the same condition.

Other University of Monastir trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07085793.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing